EXTROVIS
Amit Tiwari currently serves as the Head of Business Development at EXTROVIS since December 2023. Previously, Amit held the position of Director of Business Development at Develco Pharma Schweiz AG, overseeing the business development function, licensing operations, and portfolio strategy. A significant portion of Amit's career was spent at Amneal Pharmaceuticals as Associate Director of Global Business Development & Strategy for Europe, focusing on in-licensing and out-licensing initiatives as well as alliance management. Amit has a diverse background that includes participation in the Global Leadership Program at Ranbaxy, strategic sourcing and business development at Dr. Reddy's Laboratories, and process development projects at Tata Consultancy Services. Amit holds an M&A and Corporate Strategy degree from INSEAD, an MBA from the Indian Institute of Technology, Madras, and a BS in Manufacturing Engineering from Delhi University.
EXTROVIS
Extrovis is a fully integrated global pharmaceutical company with strong portfolio offering, comprising of Active Pharmaceutical Ingredients (APIs), Finished dosage forms (FDF) & Custom Pharmaceutical Services. Based in Switzerland, with global presence in North America, India and South America, we are supported by strong network to deliver products across geographies. Our state-of-the-art manufacturing facilities and R&D centers comply with highest international quality standards with accreditions from the USFDA, PMDA, EU and other global regulatory bodies. Our contributions in the area of education and health to financially under privileged reinforces our social commitment. Our mission is to become a reliable partner by offering high quality APIs, FDFs, custom pharmaceutical services and delivering value to our customers, stake holders and patients. Backed by our EXTROrdinary VISion, we have our eyes set on becoming a leading pharmaceutical company in the world.